MedPath

A Study Between Two Instrument Generations to Improve Adenoma Detection in Screening Colonoscopy

Completed
Conditions
Adenoma Detection Rate
Interventions
Procedure: screening colonoscopy
Registration Number
NCT03137277
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Brief Summary

Adenoma detection rate (ADR) is the most important parameter to measure outcome quality of (screening) colonoscopy. Since single improvements of imaging have not been able to improve ADR in many randomized studies, the present study tested the hypothesis that only multiple imaging improvements such as seen with two generation changes of colonoscopies - i.e. skipping one colonoscope generation - may be necessary before improvements in ADR can be measured.

The investigators will test this hypothesis in the present randomized tandem study in 7 private practices in Hamburg and Berlin, in a pure screening colonoscopy setting, aiming at inclusion of 1200 patients \> age of 55 years (screening colonoscopy cut-off in Germany). Exclusion criteria are symptomatic patients and colonoscopies planned for therapeutic reasons. Main outcome parameter is the ADR (rate of patients with at least one adenoma/all patients).

Detailed Description

The study was a prospective multicenter randomized study involving 7 private practice gastroenterology offices with a total of 14 experienced examiners (\> 2000 colonoscopies), performed between November 2013 and September 2016 (sets of instruments were made available to 3-4 centers each during 6-12 months).Study population:

Patients were selected from the screening colonoscopy list (age ≥ 55 years), with further inclusion criteria being status 1 and 2 of the ASA classification. After informed consent, patients were randomized using sealed envelopes per center to one of either of the two study groups

1. 190 C group (intervention group), examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).

2. 165 C group (control group), examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany), Each patient underwent bowel preparation in accordance with local practice of the centers. Bowel cleansing quality was segmentally assessed using a modified overall "Boston Bowel Preparation Scale". Introduction and withdrawal times were measured, and times required for biopsies and polypectomies were considered separately, i.e. overall and diagnostic only withdrawal times were recorded separately.

Polyps were documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous). Polyps were then resected using biopsy forceps or cold snare or conventional polypectomy according to local standards. Histology of resected polyps was analyzed by local private practice specialized GI pathologists according to the Vienna classification with regards to dysplasia grade and the presence of serrated adenomas; final histologic categories were hyperplastic, adenomatous \[tubulous, villous, tubulovillous, serrated (traditional or sessile serrated)\]. Small distal rectal polyps were not systematically biopsied or resected, due to a very high likelihood to be hyperplastic.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1221
Inclusion Criteria
  • screening colonoscopy, age ≥ 55 years
  • status 1 and 2 of the ASA classification
  • signed informed consent
Exclusion Criteria
  • Symptoms indicative of colorectal disease such as colonic bleeding, significant diarrhea, obstipation and change in bowel habits
  • Known colonic disease for further evaluation (e.g. inflammatory bowel disease, polyps for resection)
  • Surveillance after polypectomy or colon tumor surgery
  • Anticoagulants preventing biopsy or polypectomy
  • Poor general condition (ASA III or more)
  • Incomplete colonoscopy planned

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Olympus 190screening colonoscopyOlympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
Olympus 160/165screening colonoscopyOlympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
Primary Outcome Measures
NameTimeMethod
Adenoma detection rateday 1

adenoma detection rate (ADR) of 190 colonoscopes in comparison to 160/5 colonoscopes at the patient level (% of patients with at least one adenoma).

Secondary Outcome Measures
NameTimeMethod
Adenoma subgroups: locationthrough study completion, an average of 6 months

Adenoma subgroups due to location (right sided - down to left hepatic flexure, left sided - descending colon, sigmoid and rectum)

Adenoma subgroups: sizethrough study completion, an average of 6 months

Adenoma subgroups due to size (\< 1 cm, \> 1 cm)

Adenoma subgroups: formthrough study completion, an average of 6 months

Adenoma subgroups due to form (flat, sessile, pedunculated)

complication ratethrough study completion, an average of 6 months

Complications in both groups

Adenoma subgroups: histologythrough study completion, an average of 6 months

Adenoma subgroups due to histologic subgroups (SSA, HGIN)

Adenoma ratethrough study completion, an average of 6 months

Adenoma rate calculated at the adenoma level (all adenomas/all patients) and as the number of adenomas per adenoma carrier.

Cecal intubation ratethrough study completion, an average of 6 months

Cecal intubation rate per arm, all patients

Trial Locations

Locations (7)

Praxis Mayr / Heller

🇩🇪

Berlin, Germany

Gastroenterologie am Bayerischen Platz

🇩🇪

Berlin, Germany

Dr. Alireza Aminalai

🇩🇪

Berlin, Germany

Gastropraxis Eppendorferbaum

🇩🇪

Hamburg, Germany

Gastroenterologie-Fontanay

🇩🇪

Hamburg, Germany

Dr. Jens Aschenbeck

🇩🇪

Berlin, Germany

Gemeinschaftspraxis Hohenzollerndamm

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath